In-depth articles covering peptide science, clinical research, regulatory context, and practical research guidance. Every article is sourced from peer-reviewed literature.
The FDA will convene its Pharmacy Compounding Advisory Committee on July 23-24, 2026 to review whether BPC-157, TB-500, KPV, MOTS-c, and three other peptides should be restored to compounding-eligible status.
Explore the preclinical evidence, mechanism of action, and regulatory status of BPC-157. Understand what research shows and the gap between animal studies and human data.
What GHK-Cu is, why it's the most-studied skin peptide, the collagen-synthesis evidence, and why plasma levels of this naturally occurring tripeptide decline with age.
Compare mechanism, clinical data, weight loss outcomes, side effects, and which has stronger evidence. Includes data from SURMOUNT-5, STEP, and SURPASS trials.
What the FDA Category 2 list is, why BPC-157 was added, how it affects pharmacy compounding, and the practical implications for research availability.
What each blend contains, the rationale for combining components, and critical fact: no blend-specific clinical research exists. Learn how to evaluate blend claims.
Step-by-step guide to reconstituting peptides with BAC water. Covers the process, common mistakes, storage rules, and best practices for research use.
Explore subcutaneous vs intramuscular injection methods: anatomy, absorption, onset, duration, and practical research considerations.
Interpret COA documents: purity, sterility, potency results, HPLC data, and what researchers should verify before using any peptide.
Deep dive into pharmacokinetics, half-life definitions, elimination pathways, and why this matters for dosing schedules in research protocols.
Understand retatrutide's triple agonist mechanism, TRIUMPH trial data, comparison to semaglutide and tirzepatide, and development timeline.
Understand the structural differences, mechanism distinctions, and research landscape comparing peptides to pharmaceutical GLP-1 agonists.
Clarify what "research use only" signifies from FDA and regulatory perspectives, and the boundaries of legal and compliant research use.
Examine published evidence on combined CJC-1295 and ipamorelin use: synergies, mechanisms, and critical gaps in human clinical data.
Review available safety data from preclinical and clinical studies on research peptides, adverse event profiles, and research considerations.
How to read a Certificate of Analysis, evaluate third-party testing, identify red flags, and verify supplier claims. A research-grade guide to peptide quality.